Ebpay生命医药出版社

  • Ebpay生命

    100566

    论文已发表

    提 交 论 文


    注册即可获取Ebpay生命的最新动态

    注 册



    IF 收录期刊



    • 3.3 Breast Cancer (Dove Med Press)
    • 3.4 Clin Epidemiol
    • 2.5 Cancer Manag Res
    • 2.9 Infect Drug Resist
    • 3.5 Clin Interv Aging
    • 4.7 Drug Des Dev Ther
    • 2.7 Int J Chronic Obstr
    • 6.6 Int J Nanomed
    • 2.5 Int J Women's Health
    • 2.5 Neuropsych Dis Treat
    • 2.7 OncoTargets Ther
    • 2.0 Patient Prefer Adher
    • 2.3 Ther Clin Risk Manag
    • 2.5 J Pain Res
    • 2.8 Diabet Metab Synd Ob
    • 2.8 Psychol Res Behav Ma
    • 3.0 Nat Sci Sleep
    • 1.8 Pharmgenomics Pers Med
    • 2.7 Risk Manag Healthc Policy
    • 4.2 J Inflamm Res
    • 2.1 Int J Gen Med
    • 4.2 J Hepatocell Carcinoma
    • 3.7 J Asthma Allergy
    • 1.9 Clin Cosmet Investig Dermatol
    • 2.7 J Multidiscip Healthc



    更多详情 >>





    视频

    Symptom Severity and Treatment Satisfaction in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)

     

    Authors Schneider LD, Stevens J , Husain AM, Ito D , Fuller DS , Zee PC, Macfadden W

    Received 12 October 2022

    Accepted for publication 27 January 2023

    Published 11 March 2023 Volume 2023:15 Pages 89—101

    DOI http://doi.org/10.2147/NSS.S386021

    Checked for plagiarism Yes

    Review by Single anonymous peer review

    Peer reviewer comments 5

    Editor who approved publication: Prof. Dr. Ahmed BaHammam

    Purpose: This study aimed to investigate the molecular characteristics, antimicrobial resistance and hemolytic phenotype of Staphylococcus aureus isolated from Anhui, China.
    Objective: Idiopathic hypersomnia is a debilitating sleep disorder characterized by excessive daytime sleepiness, sleep inertia, and prolonged sleep duration. The patient burden of idiopathic hypersomnia is poorly understood. The Real World Idiopathic Hypersomnia Outcomes Study (ARISE) evaluated symptoms and treatment effectiveness/satisfaction in participants with idiopathic hypersomnia.
    Methods: ARISE was a United States–based virtual cross-sectional survey. Participants were adults 21– 65 years of age with idiopathic hypersomnia recruited from social media, the Hypersomnia Foundation website, and a patient panel. Self-assessments included the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS), Treatment Satisfaction Questionnaire for Medication, version II (TSQM-vII), and additional treatment questions. Data were analyzed for all participants and for subgroups with/without long sleep time (LST; ≥ 11 hours in 24 hours).
    Results: Of 75 participants enrolled, most were female (81.3%). The mean (SD) age was 34.1 (10.7) years and 49% had LST. Most participants took off-label prescription medications (89.3%) and/or used other measures (93.3%) to manage their symptoms. The mean (SD) ESS score was 14.5 (3.5) and the mean IHSS score was 35.2 (7.6). Treatment satisfaction was low (mean [SD] TSQM-vII score: overall, 61.9 [21.2]; with LST, 57.9 [21.4]; without LST, 66.7 [20.3]), primarily driven by dissatisfaction with treatment effectiveness. The most common classes of prescription medications used were stimulants (61.3%), wake-promoting agents (28.0%), and antidepressants (18.7%); non-prescription measures used to manage symptoms included caffeine (73.3%), planned naps (34.7%), and individual accommodations (32.0%).
    Conclusion: Overall, participants with idiopathic hypersomnia, with or without LST, had substantial symptom burden despite most of the study population taking off-label medications and using nonprescription measures to manage symptoms.
    Keywords: sleep disorder, sodium oxybate, wake-promoting agents, stimulants, antidepressants




    Download Article[PDF]